Search
Palvella Therapeutics Inc
PVLAAdd to Watchlist
139.040USD
-11.150-7.42%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.99BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Palvella Therapeutics Inc is 8.50, ranking 108 out of 385 in the Biotechnology & Medical Research industry. The average price target is 136.50, with a high of 200.00 and a low of 91.00.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
229.000
Target Price
+64.70%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Palvella Therapeutics Inc
PVLA
16
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Palvella Therapeutics Inc's price target?
Analysts forecast that Palvella Therapeutics Inc's price target is USD 136.50, with the highest forecast at USD 200.00 and the lowest forecast at USD 91.00.
How have Palvella Therapeutics IncPVLA's recent earnings per share performed?
The market expectation was USD -1.20, while Palvella Therapeutics IncPVLA's earnings per share (EPS) for the previous quarter was USD -1.07. EPS for the next quarter is expected at USD -1.16.
What is the analyst rating for Palvella Therapeutics Inc?
Based on the ratings of Palvella Therapeutics Inc's stock from 16 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.